The Novavax (NVAX) COVID-19 Vaccine NVX-CoV2373 is on its way to reaching worldwide markets.
- The Serum Institute of India (SII) and the Vaccine Alliance (Gavi) are to ensure equitable access to Novavax’s, NVX-CoV2373, vaccine worldwide across the low-, middle- and high-income countries.
- Memorandum of Understanding (MOU) between Gavi and Novavax to make available a cumulative volume of 1.1 billion doses of the Novavax vaccine to the COVAX Facility.
- The vaccine doses will be manufactured and distributed globally by Novavax and SII.
- Novavax vaccine NVX-CoV2373 is being studied in two ongoing pivotal Phase 3 clinical in the United States and Mexico, as well as in the United Kingdom (U.K.).
A positive efficacy result from its U.K. trial has been announced earlier.
News & Comments February 19, 2021